Ecabet sodium
(Synonyms: 依卡倍特钠,TA-2711) 目录号 : GC38149An antiulcerative and gastroprotective agent
Cas No.:86408-72-2
Sample solution is provided at 25 µL, 10mM.
Ecabet is an antiulcerative and gastroprotective agent.1,2,3,4 It reduces the viability of H. pylori grown under urea-supplemented acidic conditions in a concentration-dependent manner.1 Ecabet inhibits H. pylori urease activity in a pH-dependent manner (IC50s = 2.1-2.6 and >16 mg/ml at pH values of 5 and 8, respectively). It inhibits adhesion of H. pylori to MKN-28 cells when used at concentrations of 1 and 2 mg/ml.2 In vivo, ecabet (25 and 100 mg/kg, p.o.) increases levels of prostaglandin E2 in rat gastric mucosa.3 It inhibits formation of hemorrhagic lesions in esophageal mucosa and reduces gastric juice pepsin activity in a rat model of reflux induced by fore-stomach and pyloric ligation when administered at a dose of 30 mg/kg.4
1.Ito, Y., Shibata, K., Hongo, A., et al.Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pyloriEur. J. Pharmacol.345(2)193-198(1998) 2.Hayashi, S., Sugiyama, T., Yachi, A., et al.Effect of ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cellsJ. Gastroenterol.32(5)593-597(1997) 3.Kinoshita, M., Iwasaki, H., Yasoshima, A., et al.Effects of ecabet sodium (TA-2711), a new antiulcer agent, on gastrointestinal mucosal prostanoid production and morphology in ratsBiol. Pharm. Bull.16(12)1220-1225(1993) 4.Okuyama, K., Saito, N., Kume, E., et al.Ecabet sodium prevents esophageal lesions induced by the reflux of gastric juice in ratsInflammopharmacology15(2)90-94(2007)
Cas No. | 86408-72-2 | SDF | |
别名 | 依卡倍特钠,TA-2711 | ||
Canonical SMILES | O=C([C@]1(C)CCC[C@]2(C)C3=C(CC[C@@]12[H])C=C(C(C)C)C(S(=O)(O)=O)=C3)O[Na] | ||
分子式 | C20H27NaO5S | 分子量 | 402.48 |
溶解度 | DMF: 25 mg/ml,DMSO: 30 mg/ml,Ethanol: 3 mg/ml,PBS (pH 7.2): 3 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.4846 mL | 12.423 mL | 24.846 mL |
5 mM | 0.4969 mL | 2.4846 mL | 4.9692 mL |
10 mM | 0.2485 mL | 1.2423 mL | 2.4846 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet